Cells (Mar 2023)

Venom Peptides, Polyphenols and Alkaloids: Are They the Next Antidiabetics That Will Preserve β-Cell Mass and Function in Type 2 Diabetes?

  • Michele Lodato,
  • Valérie Plaisance,
  • Valérie Pawlowski,
  • Maxime Kwapich,
  • Alexandre Barras,
  • Emeline Buissart,
  • Stéphane Dalle,
  • Sabine Szunerits,
  • Jérôme Vicogne,
  • Rabah Boukherroub,
  • Amar Abderrahmani

DOI
https://doi.org/10.3390/cells12060940
Journal volume & issue
Vol. 12, no. 6
p. 940

Abstract

Read online

Improvement of insulin secretion by pancreatic β-cells and preservation of their mass are the current challenges that future antidiabetic drugs should meet for achieving efficient and long-term glycemic control in patients with type 2 diabetes (T2D). The successful development of glucagon-like peptide 1 (GLP-1) analogues, derived from the saliva of a lizard from the Helodermatidae family, has provided the proof of concept that antidiabetic drugs directly targeting pancreatic β-cells can emerge from venomous animals. The literature reporting on the antidiabetic effects of medicinal plants suggests that they contain some promising active substances such as polyphenols and alkaloids, which could be active as insulin secretagogues and β-cell protectors. In this review, we discuss the potential of several polyphenols, alkaloids and venom peptides from snake, frogs, scorpions and cone snails. These molecules could contribute to the development of new efficient antidiabetic medicines targeting β-cells, which would tackle the progression of the disease.

Keywords